Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Weight Loss: Results, Timeline & What to Expect
guidesHow much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.
Retatrutide Results: 24% Weight Loss in 48 Weeks (Trial Data)
guidesRetatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.
Semaglutide Muscle Loss: Why the Published Numbers Disagree
articleThere is no single semaglutide muscle loss figure. Four Tier 1 studies measured different populations, doses, and tissues, and the widely repeated percentages are back-calculations rather than stated trial results.
Tirzepatide Muscle Loss: What the SURMOUNT-1 DXA Data Shows
articleTirzepatide does not selectively break down muscle. In the SURMOUNT-1 DXA substudy the fat-to-lean split of weight lost matched the placebo arm, the most defensible finding in tirzepatide's body composition literature.
Retatrutide Muscle Mass Preservation: What the DEXA Data Shows
articleRetatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.